Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here

Request a Proposal  

Acute Bacterial and Skin Structure Infections (Phase IV and Oral)

Pharm-Olam was selected as a regional provider in Western Europe, Eastern Europe and South Africa on 2 studies involving hospitalized ABSSSi patients. Pharm-Olam provided a full service offering including Feasibility, Site Selection, Investigator Meetings, Regulatory, Blinded and Unblinded Monitoring, Project Management, and local Medical Monitoring services. At study close out, Pharm-Olam completed enrollment using only 41 out of the 49 planned sites.

Sponsor feedback:

“Pharm-Olam was a top performer among all the CROs involved in terms of enrollment and data quality. When we increased our targeted enrollment objectives they were able to accommodate the increased workload without issues. Their enrollment on the second study was exceptional with Pharm-Olam randomizing nearly 150% of their patient target to allow global enrollment to close earlier than expected.” - VP, Clinical Research